News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Metastatic NSCLC: Recent Developments on ALK, ROS1, and NTRK

EP. 1: Overview of Rare Driver Alterations in NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 2: Molecular Testing for NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 3: ROS1 Rearrangements in mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 4: Current Management of ROS1 rearranged NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 5: ALKA-372-001, STARTRK-1, and STARTRK-2 Trials

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 6: Future Directions for ROS1 rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 7: NTRK Gene Fusions in NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 8: Updates Informing the Management of NTRK+ NSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 9: Updates Informing the Management of ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 10: Subsequent Lines of Therapy in ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 11: Testing for ALK Rearrangements in mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

EP. 12: Future of ALK-rearranged mNSCLC

ByLyudmila A. Bazhenova, MD, University of California San Diego,Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center

August 17th 2020

Trending on OncLive

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC

Rocbrutinib Displays Durable Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC

Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC